Typhoidal Salmonella strains in Pakistan: an impending threat of extensively drug-resistant Salmonella Typhi
The aim of this study is to see the frequency, clinical presentation, and therapeutic response of extensively drug-resistant Salmonella enterica serovar Typhi and current susceptibility pattern of typhoidal Salmonella strains in our setup. This study was carried out at the Department of Medical Microbiology and Immunology and Department of Medicine, Pakistan Navy Ship (PNS) Shifa Hospital, Karachi, from January 1 to December 31, 2018. All the blood culture samples of patients (indoor and outdoor) with suspicion of enteric fever were processed. Isolates were cultured and identified using standard microbiological procedures. The antimicrobial sensitivity against the typhoidal Salmonellae was determined using Kirby-Bauer disc diffusion method as per the guidelines of Clinical and Laboratory Standards Institute (2018) and all the extensively drug-resistant (XDR) isolates were confirmed by Vitek 2 system. Clinical presentation and response to treatment of patients were followed. A total of 292 typhoidal Salmonella isolates were cultured. Resistance to ciprofloxacin against both Salmonella Typhi and Salmonella Paratyphi A was found to be very high (91%). Percentage of multidrug-resistant (MDR) isolates in Salmonella Typhi was 76% (182 isolates) and in Salmonella Paratyphi it was 34% (18 isolates). XDR isolates in Salmonella Typhi were significant that is 48% (115 isolates). Only 10 cases were given azithromycin who responded to treatment in mean 4.3 days. Out of 115 cases of XDR Salmonella Typhi, 103 patients were given parenteral meropenem and clinical response was seen in mean 5 days. The emergence and rapid spread of extensively drug-resistant Salmonella Typhi is alarming and highlights the significance of strict antimicrobial susceptibility surveillance programs with antimicrobial stewardship.
KeywordsExtensively drug resistant (XDR) Multidrug resistant (MDR) Salmonella Typhi (S. Typhi) Typhoidal Salmonella strains
Compliance with ethical standards
Ethics approval and consent to participate
Approval to conduct this study from was obtained from Institutional Ethical Committee, PNS SHIFA Hospital.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Britto CD, Wong VK, Dougan G (2018) A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS Negl Trop Dis 12:6779Google Scholar
- 7.Aziz S, Malik L (2018) Emergence of multi-resistant enteric infection in a Paediatric unit of Karachi, Pakistan. J Pak Med Assoc 5:2–84Google Scholar
- 14.Narasanna R, Chavadi M, Chandrakanth K (2018) Prevalence of multidrug-resistant Salmonella typhi in typhoid patients and detection of blaCTX-M2 and blaCTX-M9 genes in cefetoxime-mediated extended spectrum β-lactamase-producing Salmonella typhi isolates. Biomed Res 29Google Scholar
- 16.Clinical and Laboratory Standards Institute (2018) Performance standards for antimicrobial susceptibility testing 28th ed, document M100. CLSI, WayneGoogle Scholar
- 19.Shujat U, Ikram A, Hashmi IQ (2016) Current antimicrobial sensitivity pattern of typhoidal salmonellae in a referral diagnostic centre. Microbiologia Medica 31Google Scholar
- 22.Zehra NM, Satti L, Hanif F (2019) Unilateral breast abscess by an extremely drug resistant Salmonella enterica serovar Typhi: first case report from Pakistan. J Clin Diagn Res 13Google Scholar
- 23.Ryan ET, Andrews J Treatment and prevention of enteric (typhoid and paratyphoid fever). In: Post TW (ed) UpToDate. Waltham, UpToDate Inc. http://www.uptodate.com. Accessed on 22 April 2019
- 25.National Institute of Health Pakistan. Advisory for the treatment and prevention of XDR typhoid. Pakistan 2018. No.F.1-31/Misc/FEDSD/2018. Retrieved from https://www.nih.org.pk/wp-content/uploads/2019/02/Advisory-for-Typhoid-5-oct.pdf